Chair, Psychiatry | Professor, Psychology | Professor, Psychiatry | Member of the Graduate Faculty
Jordan Karp, MD, is the Department Chair, Professor of Psychiatry, and Medical Director for Behavioral Health Technology. He is an expert in the fields of geriatric psychiatry, depression treatment, and suicide prevention. Dr. Karp’s priorities for the Department include: providing the best care possible to our patients and their families today; preparing the next generation of psychiatrists to provide better care in the future; produce the advancements in knowledge required to improve our ability to diagnose, treat, and ultimately prevent mental illness; and engage with diverse stakeholders to assure our workforce represents and meets the needs of our community and promotes social justice. Prior to joining the University of Arizona, Dr. Karserved as a professor of psychiatry, anesthesiology and clinical and translational science at the University of Pittsburgh School of Medicine, where he directed the Late-Life Depression Prevention and Treatment Research Program, served as Director of Medical Student Mental Health Services, and was program director for the geriatric psychiatry fellowship.
A prestigious grant titled 'An Open-label, Long-term, Safety and Efficacy Study' has been awarded by J&J Neuroscience (Janssen) to Dr. Jordan Karp, Professor and Chair for the Department of Psychiatry at the University of Arizona. Dr. Karp, a renowned psychiatrist and professor, will lead the project, which focuses on investigating the effectiveness of aticaprant as an adjunctive therapy for adults with Major Depressive Disorder (MDD) and moderate-to-severe anhedonia, who have not responded well to current antidepressant therapy.
Key aspects of the grant:
1. The project, led by Dr. Jordan Karp, aims to evaluate the safety and efficacy of aticaprant as an adjunctive therapy for adults with MDD and anhedonia.
2. Aticaprant will be tested against a placebo as an add-on treatment to an antidepressant.
3. The study targets participants who have not responded adequately to current antidepressant therapy with an SSRI or SNRI.
4. The grant is focused on improving depressive symptoms and advancing knowledge in mental health treatment.